ARRY discontinues Phase 3 MILO trial. RIGL Phase 3 data due mid 2016 + CANF update

Apr 02, 2016 No Comments

Updates to the Company Pipeline Database for April 1, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ARRY 3.00 Binimetinib – MILO Recurrent low-grade serous ovarian cancer (LGSOC) Phase 3 Phase 3 trial discontinued April 2016 CANF 2.77 CF101 Rheumatoid arthritis Phase 3 Phase 3 to be initiated 2Q […]

Read more

GNCA up 95% on Phase 2 data release + updates for AMRN FLML NDRM RDHL

Apr 01, 2016 No Comments

Updates to the Company Pipeline Database for March 31, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AMRN 1.53 Vascepa REDUCE-IT outcomes trial High Triglycerides With Mixed Dyslipidemia REDUCE-IT outcomes trial REDUCE-IT outcomes trial interim efficacy look by the independent Data Monitoring Committee (DMC) due around the end of […]

Read more

DVAX PDUFA set for September 15. LXRX and RDUS submit NDA filings + updates for AFMD ALDX ATOS EARS LIFE RXII TKAI updates

Mar 31, 2016 No Comments

Updates to the Company Pipeline Database for March 30, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AFMD 3.69 AFM13 Hodgkin Lymphoma Phase 2 Phase 2a interim data due 2Q 2016. Final data due by the end of 2016 ALDX 4.05 NS2 Noninfectious anterior uveitis Phase 2 Phase 2 […]

Read more

ACAD positive Adcom vote. OPK receives CRL. PTIE DRRX resubmit NDA + AEZS AMPE ARLZ AUPH BLRX CBAY CLBS CRBP KERX MIRN OHRP RNN VBLT updates

Mar 30, 2016 No Comments

Updates to the Company Pipeline Database for March 29, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ACAD 23.81 Pimavanserin Parkinson’s disease psychosis (PDP) PDUFA PDUFA date May 1 2016 of Pimavanserin for Parkinson’s disease psychosis (PDP) – under priority review. Psychopharmacologic Drugs Advisory Committee Meeting March 29 2016 […]

Read more

ALDR release positive Phase 2b data. PBYI NDA filing delayed till mid year. APRI miss endpoints in Phase 2 trial + updates for AERI BVXV NEOT OXGN

Mar 28, 2016 No Comments

Updates to the Company Pipeline Database for March 24, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AERI 11.65 Roclatan – Mercury trials Glaucoma Phase 3 Phase 3 Mercury 1 data due 3Q 2016. Mercury 2 trial data due 2Q 2017 ALDR 25.70 ALD403 Chronic Migraine Phase 2b Phase […]

Read more

PTLA down 29% on Phase 3 data release + updates for ADRO AXSM CYTX DMTX DSCO NVIV REPH SNGX SNSS

Mar 24, 2016 No Comments

Updates to the Company Pipeline Database for March 24, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ADRO 12.12 Epacadostat and CRS-207 – SEASCAPE Ovarian cancer Phase 1/2 Phase 1/2 dosing initiated March 2016 AXSM 8.88 AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3 Phase 3 […]

Read more

Pipeline updates for ACRS BLRX CERC DPRX IRWD ITEK OTIC SPHS STEM

Mar 24, 2016 No Comments

Updates to the Company Pipeline Database for March 23, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ACRS 15.00 A-101 Seborrheic keratosis (SK) Phase 3 Phase 3 data due 3Q 2016 ACRS 15.00 A-101 Common warts (verruca vulgaris) Phase 2 Phase 2 data due 3Q 2016 BLRX 1.15 BL-8040 […]

Read more

ANAC PDUFA January 7 2017. INSY PDUFA delayed till July 1. GLMD Phase 2b data timeline extended + ARQL update

Mar 22, 2016 No Comments

Updates to the Company Pipeline Database for March 22, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ANAC 59.99 Crisaborole Topical Ointment Mild-to-moderate atopic dermatitis PDUFA PDUFA January 7 2017 ARQL 1.73 Tivantinib (ARQ 197) METIV-HCC trial Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy Phase […]

Read more

BMRN release mixed Phase 3 data + updates for BLPH XTLB

Mar 21, 2016 No Comments

Updates to the Company Pipeline Database for March 21, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary BLPH 2.84 INOpulse delivery device Pulmonary Arterial Hypertension (PAH) Phase 3 Company indicated in March 2016 that they are preparing to enrol patients in the Phase 3 trial BLPH 2.84 INOpulse delivery […]

Read more